Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Vet Ophthalmol. 2021 Jan 7;24(Suppl 1):16–33. doi: 10.1111/vop.12858

Figure 1.

Figure 1.

Schematic cross-section of an eye showing potential targets for gene and cell glaucoma therapies: (1) Increased aqueous humor outflow, (2) decreased aqueous humor production, (3) preventing gonioimplant bleb fibrosis, (4) RGC neuroprotection and neuroregeneration, (5) modification of biomechanical properties of sclera, lamina cribrosa, and cornea, and (6) inhibition of inflammation and PIFVM formation.